![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » AbbVie, Gedeon Richter Forge Pact to Develop Neuropsychiatric Drugs
AbbVie, Gedeon Richter Forge Pact to Develop Neuropsychiatric Drugs
AbbVie and Hungary’s Gedeon Richter have struck a deal to develop therapies for neuropsychiatric diseases, building on their existing 15-year partnership.
The new collaboration will focus on AbbVie’s Vraylar (cariprazine) and will “explore novel chemistry to identify new dopamine-receptor modulators,” said Tom Hudson, AbbVie’s chief scientific officer.
Financial terms of the expanded partnership deal were not disclosed, but Richter will receive an upfront payment.
Vraylar is FDA-approved for adults with bipolar 1 disorder, bipolar depression and schizophrenia. AbbVie is currently seeking expanded approval for Vraylar as an adjunct treatment for major depressive disorder.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct